Filled in 6 bare reference(s) with reFill 2 |
Citation bot (talk | contribs) Altered title. Add: pmc, pmid. Removed URL that duplicated identifier. | Use this bot. Report bugs. | Suggested by LeapTorchGear | Category:AfC pending submissions by age/0 days ago | #UCB_Category 23/104 |
||
(One intermediate revision by one other user not shown) | |||
Line 1: | Line 1: | ||
⚫ | |||
⚫ | |||
{{AFC submission|d|corp|u=Pomelosol|ns=118|decliner=DoubleGrazing|declinets=20240326142312|small=yes|ts=20240326141257}} <!-- Do not remove this line! --> |
|||
{{Short description|Nasdaq-listed biopharmaceutical company}} |
{{Short description|Nasdaq-listed biopharmaceutical company}} |
||
{{Draft topics|medicine-and-health}} |
{{Draft topics|medicine-and-health}} |
||
{{AfC topic|org}} |
{{AfC topic|org}} |
||
{{AfC submission|||ts=20240403151046|u=Pomelosol|ns=118}} |
|||
⚫ | |||
⚫ | |||
MoonLake Immunotherapeutics (‘MoonLake’) is a clinical-stage biopharmaceutical company, headquartered in Zug, Switzerland, focused on developing medicines for inflammatory diseases. The Company was founded in 2021 when Sonelokimab was in-licensed from Merck KGaA, of Darmstadt, Germany.<ref>{{Cite web|url=https://www.zefix.ch/en/search/entity/list/firm/1477715|title=ZefixWebApp|website=www.zefix.ch}}</ref><ref>{{Cite web |title=Merck Statement on the Out-licensing Agreement for Investigational sonelokimab (M1095) |url=https://www.merckgroup.com/en/news/statement-on-out-licensing-agreement-sonelokimab-03-05-2021.html}}</ref><ref>{{Cite web|url=https://www.fiercebiotech.com/biotech/moonlake-debuts-cosentyx-challenger-from-merck-kgaa|title=MoonLake debuts with Cosentyx challenger from Merck KGaA | Fierce Biotech}}</ref> The initial investors were BVF Partners LP, Merck KGaA, Florian Schönharting, Simon Sturge, Arnout Ploos van Amstel, Dr. Jorge Santos da Silva, and Dr. Kristian Reich.<ref>{{Cite web|url=https://www.sec.gov/ix?doc=/Archives/edgar/data/0001821586/000121390021051257/ea147872-8k_helixacq.htm|title=XBRL Viewer|website=www.sec.gov}}</ref><ref>{{Cite web |title=sec.gov, prelim. proxy statement |url=https://www.sec.gov/Archives/edgar/data/1821586/000121390021055441/prem14a_helixacq.htm}}</ref><ref>{{Cite web|url=https://pharmaphorum.com/views-and-analysis/inside-moonlakes-raid-on-merck-kgaas-inflammatory-disease-hopeful-sonelokimab|title=Inside |
MoonLake Immunotherapeutics (‘MoonLake’) is a clinical-stage biopharmaceutical company, headquartered in Zug, Switzerland, focused on developing medicines for inflammatory diseases. The Company was founded in 2021 when Sonelokimab was in-licensed from Merck KGaA, of Darmstadt, Germany.<ref>{{Cite web|url=https://www.zefix.ch/en/search/entity/list/firm/1477715|title=ZefixWebApp|website=www.zefix.ch}}</ref><ref>{{Cite web |title=Merck Statement on the Out-licensing Agreement for Investigational sonelokimab (M1095) |url=https://www.merckgroup.com/en/news/statement-on-out-licensing-agreement-sonelokimab-03-05-2021.html}}</ref><ref>{{Cite web|url=https://www.fiercebiotech.com/biotech/moonlake-debuts-cosentyx-challenger-from-merck-kgaa|title=MoonLake debuts with Cosentyx challenger from Merck KGaA | Fierce Biotech}}</ref> The initial investors were BVF Partners LP, Merck KGaA, Florian Schönharting, Simon Sturge, Arnout Ploos van Amstel, Dr. Jorge Santos da Silva, and Dr. Kristian Reich.<ref>{{Cite web|url=https://www.sec.gov/ix?doc=/Archives/edgar/data/0001821586/000121390021051257/ea147872-8k_helixacq.htm|title=XBRL Viewer|website=www.sec.gov}}</ref><ref>{{Cite web |title=sec.gov, prelim. proxy statement |url=https://www.sec.gov/Archives/edgar/data/1821586/000121390021055441/prem14a_helixacq.htm}}</ref><ref>{{Cite web|url=https://pharmaphorum.com/views-and-analysis/inside-moonlakes-raid-on-merck-kgaas-inflammatory-disease-hopeful-sonelokimab|title=Inside MoonLake's raid on Merck KGaA's inflammatory disease hopeful sonelokimab|website=pharmaphorum}}</ref> |
||
Sonelokimab is an investigational Nanobody designed to treat inflammatory diseases by inhibiting the naturally occurring IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation. In addition, Sonelokimab is designed to target inflammation sites directly and, due to its smaller size compared to typical monoclonal antibodies, potentially offers better tissue penetration.<ref>{{Cite journal |last=Iznardo |first=H. |date=12 August 2021 |title=Dual inhibition of IL-17A and IL-17F in psoriatic disease |
Sonelokimab is an investigational Nanobody designed to treat inflammatory diseases by inhibiting the naturally occurring IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation. In addition, Sonelokimab is designed to target inflammation sites directly and, due to its smaller size compared to typical monoclonal antibodies, potentially offers better tissue penetration.<ref>{{Cite journal |last=Iznardo |first=H. |date=12 August 2021 |title=Dual inhibition of IL-17A and IL-17F in psoriatic disease |journal=Therapeutic Advances in Chronic Disease |volume=12 |doi=10.1177/20406223211037846|pmid=34408825 |pmc=8366125 }}</ref><ref name=":0">{{Cite web|url=https://www.europeanpharmaceuticalreview.com/news/153361/sonelokimab-shows-promise-in-phase-ii-psoriasis-trial/|title=Sonelokimab shows promise in Phase II psoriasis trial}}</ref> |
||
In May 2021, positive results of a Phase IIb trial of Sonelokimab for the treatment of patients with moderate to severe psoriasis were published in the peer-reviewed medical journal, The Lancet.<ref name=":0" /><ref>{{Cite journal |last=Papp |first=K.A. |title=IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study |url=http://www.thelancet.com |journal=[[The Lancet]] |date=2021 |volume=397 |issue=10284 |pages=1564–1575|doi=10.1016/S0140-6736(21)00440-2 }}</ref> |
In May 2021, positive results of a Phase IIb trial of Sonelokimab for the treatment of patients with moderate to severe psoriasis were published in the peer-reviewed medical journal, The Lancet.<ref name=":0" /><ref>{{Cite journal |last=Papp |first=K.A. |title=IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study |url=http://www.thelancet.com |journal=[[The Lancet]] |date=2021 |volume=397 |issue=10284 |pages=1564–1575|doi=10.1016/S0140-6736(21)00440-2 |pmid=33894834 }}</ref> |
||
MoonLake is progressing the clinical development of Sonelokimab for the treatment of inflammatory diseases, including hidradenitis suppurativa<ref>{{Cite web |title=Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa |date=13 November 2023 |url=https://clinicaltrials.gov/study/NCT05322473}}</ref> and psoriatic arthritis.<ref>{{Cite web |title=Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis |date=15 November 2023 |url=https://clinicaltrials.gov/study/NCT05640245}}</ref> |
MoonLake is progressing the clinical development of Sonelokimab for the treatment of inflammatory diseases, including hidradenitis suppurativa<ref>{{Cite web |title=Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa |date=13 November 2023 |url=https://clinicaltrials.gov/study/NCT05322473}}</ref> and psoriatic arthritis.<ref>{{Cite web |title=Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis |date=15 November 2023 |url=https://clinicaltrials.gov/study/NCT05640245}}</ref> |
Latest revision as of 17:41, 4 April 2024
MoonLake Immunotherapeutics (‘MoonLake’) is a clinical-stage biopharmaceutical company, headquartered in Zug, Switzerland, focused on developing medicines for inflammatory diseases. The Company was founded in 2021 when Sonelokimab was in-licensed from Merck KGaA, of Darmstadt, Germany.[1][2][3] The initial investors were BVF Partners LP, Merck KGaA, Florian Schönharting, Simon Sturge, Arnout Ploos van Amstel, Dr. Jorge Santos da Silva, and Dr. Kristian Reich.[4][5][6]
Sonelokimab is an investigational Nanobody designed to treat inflammatory diseases by inhibiting the naturally occurring IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation. In addition, Sonelokimab is designed to target inflammation sites directly and, due to its smaller size compared to typical monoclonal antibodies, potentially offers better tissue penetration.[7][8]
In May 2021, positive results of a Phase IIb trial of Sonelokimab for the treatment of patients with moderate to severe psoriasis were published in the peer-reviewed medical journal, The Lancet.[8][9]
MoonLake is progressing the clinical development of Sonelokimab for the treatment of inflammatory diseases, including hidradenitis suppurativa[10] and psoriatic arthritis.[11]
In April 2022, MoonLake combined with Helix Acquisition Corp., a special purpose acquisition vehicle, becoming a Nasdaq-listed company with the ticker symbol MLTX.[12][13][14]
References
- ^ "ZefixWebApp". www.zefix.ch.
- ^ "Merck Statement on the Out-licensing Agreement for Investigational sonelokimab (M1095)".
- ^ "MoonLake debuts with Cosentyx challenger from Merck KGaA | Fierce Biotech".
- ^ "XBRL Viewer". www.sec.gov.
- ^ "sec.gov, prelim. proxy statement".
- ^ "Inside MoonLake's raid on Merck KGaA's inflammatory disease hopeful sonelokimab". pharmaphorum.
- ^ Iznardo, H. (12 August 2021). "Dual inhibition of IL-17A and IL-17F in psoriatic disease". Therapeutic Advances in Chronic Disease. 12. doi:10.1177/20406223211037846. PMC 8366125. PMID 34408825.
- ^ a b "Sonelokimab shows promise in Phase II psoriasis trial".
- ^ Papp, K.A. (2021). "IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study". The Lancet. 397 (10284): 1564–1575. doi:10.1016/S0140-6736(21)00440-2. PMID 33894834.
- ^ "Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa". 13 November 2023.
- ^ "Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis". 15 November 2023.
- ^ "MoonLake Immunotherapeutics AG announces closing business".
- ^ "Nasdaq: MoonLake Immunotherapeutics Class A Ordinary Shares".
- ^ "MoonLake over the moon with $230M SPAC deal for llama antibodies to challenge Novartis' Cosentyx | Fierce Biotech".